CORALVILLE, Iowa--(BUSINESS WIRE)--Corvida Medical, an emerging medical device corporation creating technologies to ensure a safer environment for healthcare providers and their patients, has launched a multi-center research study. Funded by the National Cancer Institute (NCI) as part of a series of Small Business Innovation Research (SBIR) grants, the aim of the study is to demonstrate the improvements that Corvida’s new technology could bring to the safe handling of hazardous drugs. Corvida is now seeking study participants to join the country’s leading cancer centers in a one day evaluation of the medical devices used to improve safe handling of hazardous drugs.
Over 5.5 million healthcare workers are at risk of exposure annually to hazardous pharmaceuticals during the preparation and delivery of chemotherapy. Studies have shown that exposure to these hazardous drugs can cause serious health problems, “such as cancers, reproductive and developmental problems…and other adverse events that can be irreversible even after low-level exposures,” according to the Occupational Safety & Health Administration (OSHA), National Institute of Occupational Safety & Health (NIOSH), and Joint Commission.
The research partners involved in this study represent key opinion leaders in the field of oncology pharmacy and nursing who continuously pursue advances in cancer care and the processes used to deliver that care to patients. The Corvida NCI-funded SBIR study will evaluate improvements that the company’s Closed System Transfer Device (CSTD) technology could bring to the safe handling of hazardous drugs. NIOSH has defined a CSTD as a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.
The NCI has awarded a series of grants totaling just under $5 million to Corvida Medical in full support of the company’s initiatives to make cancer care safer via a proprietary suite of patented medical devices, including most recently a $3 million NCI Bridge Award. Grant funding provides sites with payment for participation as well as opportunities to collaborate in publication of findings.
Kent Smith, President and CEO of Corvida Medical, commented, “The grants from the NCI will help us advance Corvida’s soon-to-be-launched family of Halo™ brand CSTD products. The NCI SBIR study is a significant effort by the company to get leading cancer institutions in the U.S. to explore applications of Halo and to demonstrate forward movement in safe handling.”
Corvida Medical is accepting applications to participate in this NCI-funded SBIR study opportunity. Interested applicants can find out more by visiting CorvidaMedical.com, emailing firstname.lastname@example.org, calling 800-604-2235, or visiting the company at the ASHP Mid-year meeting in Anaheim, Booth 1481 from December 8-10.
Headquartered in Coralville, Iowa, Corvida Medical innovates intelligent technologies that represent the next generation of excellence in safe handling of hazardous drugs. The company addresses the problems inherent in current CSTDs and develops smarter, simpler solutions to improve safety, productivity and quality for providers and patients. Corvida’s first medical device, a novel new Closed System Transfer Device – the Halo™ -- will be available in 2015. The Halo is not currently cleared for sale in the U.S.